Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
NCT00554788
Completed
This phase III trial is studying the side effects and how well giving combination chemotherapy together with autologous stem cell transplant and/or radiation therapy works in treating young patients with extraocular retinoblastoma. Giving chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and/or bone marrow and stored. More chemotherapy is given t... Read More
Gender:
ALL
Ages:
10 years and below
Trial Updated:
01/03/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +72 locations
Conditions: Extraocular Retinoblastoma
Register for Updates
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
NCT03105336
Completed
This study will enroll approximately 160 adult participants who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is made from the participants own white blood cells which are genetically modified and grown to fight cancer. An objective response rate of 70% is targeted.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +18 locations
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma
Register for Updates
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
NCT00085735
Completed
This randomized phase III trial is studying how well standard-dose radiation therapy works compared to reduced-dose radiation therapy in children 3-7 years of age AND how well standard volume boost radiation therapy works compared to smaller volume boost radiation therapy when given together with chemotherapy in treating young patients who have undergone surgery for newly diagnosed standard-risk medulloblastoma. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemo... Read More
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
01/03/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +196 locations
Conditions: Medulloblastoma
Register for Updates
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
NCT03434769
Active Not Recruiting
The purpose of this study is to determine if it is possible to treat your cancer with a new type of T cell-based immunotherapy (therapy that uses your immune system to treat the cancer). T cells are a type of white blood cell that helps the body fight infections. This treatment uses T cells already present within your body that have been modified outside of the body and returned to target your cancer. This type of treatment is sometimes referred to as adoptive cell transfer (ACT). In this study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Washington University School of Medicine, St. Louis, Missouri +1 locations
Conditions: Non-Hodgkin Lymphoma
Register for Updates
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
NCT01025089
Active Not Recruiting
The main purpose of this study is to find out the good and the bad effects that the combination of cetuximab with the traditional chemotherapy regimen of cisplatin, doxorubicin, and cyclophosphamide has when given to patients with later stage thymoma or thymic carcinoma before surgery. The physicians will also look at changes in genes in the tumor that may relate to the effectiveness of cetuximab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: City of Hope Medical Center, Duarte, California +7 locations
Conditions: Thymoma, Thymic Carcinoma, Clinical Masaoka Stage II to IVA
Register for Updates
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
NCT03712878
Active Not Recruiting
This phase II trial studies how well a 2-step approach to stem cell transplant works in treating patients with blood cancers. Giving chemotherapy and total body irradiation before a lymphocyte (white blood cell) and stem cell transplant helps stop the growth of cells in the bone marrow including normal blood-forming cells (stem cells) and cancer cells. By giving the donor cells in two steps, the dose of lymphocytes given can be tightly controlled and they can be made more tolerant to the body. W... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Register for Updates
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
NCT06447987
Recruiting
This phase Ib trial tests the safety, side effects, and effectiveness of humanized (hu)CD19-chimeric antigen receptor (CAR) T cell therapy in treating patients with CD19 positive B-cell acute lymphoblastic leukemia (ALL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). CAR T-cell therapy is a treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/29/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Register for Updates
A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia
NCT05757310
Recruiting
This phase I trial evaluates the safety and feasibility of using a reduced-intensity regimen of cyclophosphamide, pentostatin, and anti-thymocyte globulin prior to a CD4+ T-cell depleted haploidentical hematopoietic cell transplant (haploHCT) for the treatment of patients with severe aplastic anemia that does not respond to treatment (refractory) or that has come back (recurrent). Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonuc... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
12/29/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Recurrent Severe Aplastic Anemia, Refractory Severe Aplastic Anemia
Register for Updates
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
NCT00670358
Completed
RATIONALE: Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, eit... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/26/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Lymphoma
Register for Updates
Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
NCT05289167
Active Not Recruiting
This is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the criteria defined in our standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Subjects will receive a standard of care conditioning regimen. Subjects will receive investigational PTCy, investigational bort... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
12/24/2024
Locations: Northwell Health, New Hyde Park, New York
Conditions: Graft-versus-host Disease
Register for Updates
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
NCT00902044
Active Not Recruiting
Patients have a type of cancer called sarcoma. Because there is no standard treatment for the patients cancer at this time or because the currently used treatments do not work fully in all cases, patients are being asked to volunteer to take part in a gene transfer research study using special immune cells. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from diseases caused by germs or toxic substances. T... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/23/2024
Locations: Houston Methodist Hospital, Houston, Texas +1 locations
Conditions: Sarcoma
Register for Updates
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
NCT03153410
Completed
The purpose of this study is to evaluate whether combining cyclophosphamide (CY), pembrolizumab, GVAX and IMC-CS4 is effective and safe in patients with borderline resectable pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates